Eloralintide 10mg,10mg/Vial,10Vials/Kit (Box),Weight management

Eloralintide is an investigational, once-weekly injectable medication developed by Eli Lilly that is being studied for obesity and weight management. Acting as a selective amylin receptor agonist, it reduces appetite and promotes a feeling of fullness.

How It works ?

Unlike other amylin-based therapies that also interact with calcitonin receptors, eloralintide selectively targets human amylin receptors. This selectivity, combined with its long half-life of about two weeks, is believed to offer meaningful weight loss with fewer gastrointestinal side effects than some existing GLP-1 and dual-agonist treatments.

Efficacy & Clinical Trials

Results from a 48-week Phase 2 clinical trial in adults with obesity or overweight showed significant, dose-dependent weight loss:
 

• 9 mg dose: Achieved an average body weight reduction of approximately 20% (roughly 47 lbs) from baseline.
• Secondary benefits: The trial also showed improvements in cardiometabolic markers, including blood pressure, waist circumference, and inflammation.
• Side effects: The most commonly reported side effects were nausea and fatigue, with severity and incidence increasing at higher doses.

Current Status

Eloralintide is not yet approved by the FDA or other regulatory agencies. Eli Lilly is actively evaluating the drug in Phase 3 programs and exploring its use both as a monotherapy and as a complementary treatment in combination with incretin therapies.